Sibrotuzumab
Sibrotuzumab
Sibrotuzumab (pronunciation: si-bro-tu-zu-mab) is a monoclonal antibody designed for the treatment of certain types of cancer. It was developed by Boehringer Ingelheim, a German pharmaceutical company.
Etymology
The name "Sibrotuzumab" is derived from the International Nonproprietary Names (INN), where "si-" refers to its source (S. cerevisiae), "bro-" refers to its target (brother of Regulator of Imprinted Sites), "tu-" indicates its tumor specificity, and "-mab" is a common suffix for monoclonal antibodies.
Mechanism of Action
Sibrotuzumab works by binding to the Fibroblast Activation Protein (FAP), a protein that is overexpressed in many types of tumors. By binding to FAP, Sibrotuzumab inhibits the growth and proliferation of cancer cells.
Clinical Trials
Sibrotuzumab has been tested in several clinical trials for its efficacy in treating various types of cancer, including colorectal cancer and lung cancer. However, as of now, it has not been approved for use by any major regulatory authority.
Related Terms
External links
- Medical encyclopedia article on Sibrotuzumab
- Wikipedia's article - Sibrotuzumab
This WikiMD article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski